Browse by Audience
Skip to content
Papers of the Week
Nitrous oxide as an adjunctive therapy in major depressive disorder: a randomized controlled double-blind pilot trial.
Abstract
Major depressive disorder (MDD) is related to glutamatergic dysfunction. Antagonists of glutamatergic N-methyl-D-aspartate receptor (NMDAR), such as ketamine, have antidepressant properties. Nitrous oxide (N2O) is also a NMDAR antagonist. Thus, this study aimed to evaluate the effects of augmenting antidepressant treatment with N2O.